Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 77.19 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 52.62K shares, a 13.64% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 24.57K shares, a 0.64% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 33.44K shares, a 30.49% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 85.90K shares, a 34.61% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 205.00K shares, a 11.06% decline from fiscal 2024.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 230.50K shares, a 900.03% increase from fiscal 2023.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 23.05K shares.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 33.15K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 52.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 77.19K shares 10-Q · filed 2026-08-11 | 110.63K shares derived: sum of 3 quarters · filed 2026-08-11 | 196.53K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 24.57K shares 10-Q · filed 2026-05-12 | 58.01K shares derived: sum of 2 quarters · filed 2026-05-12 | 143.91K shares derived: sum of 3 quarters · filed 2026-05-12 | 204.84K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 33.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 119.34K shares derived: sum of 2 quarters · filed 2026-03-24 | 180.27K shares derived: sum of 3 quarters · filed 2026-03-24 | 205.00K shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 85.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 146.82K shares derived: sum of 2 quarters · filed 2025-11-13 | 171.55K shares 10-Q · filed 2025-11-13 | 197.18K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 60.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 85.66K shares 10-Q · filed 2025-08-11 | 111.29K shares derived: sum of 3 quarters · filed 2025-08-11 | 242.64K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 24.73K shares 10-Q · filed 2025-05-09 | 50.36K shares derived: sum of 2 quarters · filed 2025-05-09 | 181.71K shares derived: sum of 3 quarters · filed 2025-05-09 | 202.53K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 25.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 156.98K shares derived: sum of 2 quarters · filed 2025-03-24 | 177.80K shares derived: sum of 3 quarters · filed 2025-03-24 | 230.50K shares 10-K · filed 2025-03-24 |
| 2024-09-30 | 131.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | 152.17K shares derived: sum of 2 quarters · filed 2024-11-18 | 204.87K shares 10-Q · filed 2024-11-18 | |
| 2024-06-30 | 20.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 73.52K shares 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | 52.70K shares 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | 23.05K shares 10-K · filed 2024-03-18 | |||
| 2014-12-31 | 33.15K shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |